未找到相关数据
Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naive, EGFRm NSCLC with CNS metastases.
被引：12
作者：
Ahn, Myung-Ju
Kim, Dong-Wan
Cho, Byoung Chul
Kim, Sang-We
Lee, Jong-Seok
Ahn, Jin Seok
Kim, Tae Min
Lin, Chia-Chi
Kim, HyeRyun
John, Tom
Kao, Stephen Chuan-Hao
Goldman, Jonathan Wade
Su, Wu-Chou
Natale, Ronald B.
Overend, Philip
Yang, Zhenfan
Yang, James Chih-Hsin
机构：
[1] Sungkyunkwan Univ, Sch Med, Div Hematol & Oncol, Dept Med,Samsung Med Ctr, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[5] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[6] Sungkyunkwan Univ, Sch Med, Div Hematol & Oncol, Dept Med,Samsung Med Ctr, Seoul, South Korea
[7] Natl Taiwan Univ Hosp, Taipei, Taiwan
[8] Yonsei Univ, Div Med Oncol, Dept Internal Med, Coll Med, Seoul, South Korea
[9] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia
[10] Chris OBrien Lifehouse, Sydney, NSW, Australia
[11] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[12] Natl Cheng Kung Univ NCKU Hosp, Tainan, Taiwan
[13] Cedars Sinai Outpatient Canc Ctr, Los Angeles, CA USA
[14] AstraZeneca, Melbourne, Vic, Australia
[15] AstraZeneca, Innovat Ctr China, Innovat Med & Early Dev, Shanghai, Peoples R China
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.2006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 [肿瘤学];
摘要：
2006
引用
收藏
页数：5
相关论文